Effect of Compound Xueshuantong Combined with Bevacizumab on Prima-ry and Secondary Outcomes of Wet Age-related Macular Degeneration

REN Gang; GAN Guoju

doi:10.3969/j.issn.1002-3429.2024.13.020

Abstract：Objective To explore the clinical effect of compound Xueshuantong and Bevacizumab in the treatment of wet age-related macular degeneration(wAMD).Methods A total of 62 wAMD patients admitted from April 2021 to May 2023 were randomly divided into two groups,with 31 patients in each group.The Bevacizumab group was treated with Bevaci-zumab,and the combined group was treated with compound Xueshuantong combined with Bevacizumab.Both groups were treated for 3 months.The clinical efficacy,best corrected visual acuity(BCVA)logarithm of the minimum angle of resolution(LogMAR),foveal retinal thickness(CRT),ocular hemodynamics[peak systolic velocity(PSV),end-diastolic velocity(EDV),resistance index(RI)],serum factors[vascular endothelial growth factor(VEGF),interleukin-1(IL-1),inter-leukin-6(IL-6),interleukin-17(IL-17),vascular endothelial growth inhibitor(VEGI),tumor necrosis factor-α(TNF-α)]and adverse reactions were compared between the two groups.Results The total effective rate of combination group was 93.55%(29/31),which was higher than that of Bevacizumab group[70.97%(22/31)](P＜0.05).At 1 and 3 months after treatment,BCVA(LogMAR)in combination group was better than that in Bevacizumab group,and CRT was lower than that in Bevacizumab group(P＜0.05).At 1 and 3 months after treatment,RI,IL-6,TNF-α,IL-1,IL-17 and VEGF in combination group were lower than those in Bevacizumab group,while PSV,EDV and VEGI were higher than those in Bevaci-zumab group(P＜0.05).The injection times of Bevacizumab in combination group was less than that in Bevacizumab group(P＜0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion In the treatment of wAMD,compound Xuesuantong and Bevacizumab can effectively regulate the level of angio-genic factors,inhibit pro-inflammatory factors,improve ocular hemodynamics,reduce the number of Bevacizumab injections,and thus alleviate local lesions,and the treatment is safe.